



Microbiota Intervention to Change the Response in Parkinson's Disease (Micro PD)



Did you know there may be a connection between Parkinson's disease and the gut microbiome?

Are you currently taking Carbidopa/Levodopa for PD?*

Do you have symptoms that come and go with medications throughout the day?

Overview: The bacteria that live in our gastrointestinal system, collectively known as the gut microbiome, may be abnormal in Parkinson's disease, and may contribute to worsening symptoms and disease. The Micro PD study is trying to understand the role of "resetting" the gut microbiome in Parkinson's disease and the role of reducing bacteria through an antibiotic that only acts within the GI tract and may improve absorption of levodopa.

Participants Will Receive:

- Either an antibiotic that only acts within the GI tract or a placebo
- Financial compensation per each remote visit completed

If you are interested or have any questions, call or email a member of the study team:

- Raymundo Picos, Study Coordinator
 - Email: Raymundo.Picos@ucsf.edu
 - Phone: 415-514-6257

UCSF Weill Institute for | Department of
Neurosciences | Neurology

*Medicines that include carbidopa / levodopa are: Sinemet, Sinemet CR, Rytary, Stalevo